Clinical trials: Levodopa
Parkinson's Disease
A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients
To investigate the safety of once-daily repeated transdermal administration of SPM 962 within a dose range of 4.5 to 36.0 mg/day (54-week treatment period) in Parkinson's disease (PD) patients treated concomitantly with L-dopa in…
- Trial name
- NCT01631825
- Testing
- SPM 962
- Where
- 8 sites in Japan
- Volunteers
- 321 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease, Dyskinesia, Drug-Induced
Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced…
- Conditions
- Parkinson Disease, Dyskinesia, Drug-Induced, Levodopa
- Trial name
- NCT01173731
- Testing
- AFQ056
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Dyskinesias, Parkinson Disease
Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).
- Conditions
- Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders
- Trial name
- NCT01491932
- Testing
- AFQ056
- Where
- 32 sites in United States, Austria and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5…
- Trial name
- NCT01631812
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson's Disease
A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients
Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.
- Trial name
- NCT01628965
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 143 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Compassionate Use Study of Pergolide in Patients With Parkinson's Disease
This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.
- Trial name
- NCT00624741
- Testing
- Pergolide
- Sponsor
- Bausch Health Americas, Inc.